MEDI 312-Discovery of YM155, a novel survivin suppressant for the treatment of cancer

被引：0
|
作者：
Kinoyama, Isao [1 ]
Matsuhisa, Akira [1 ]
Nakahara, Takahito [1 ]
Takeuchi, Masahiro [1 ]
Shirasuna, Kenna [1 ]
Minematsu, Tsuyoshi [1 ]
Asai, Norio [1 ]
Matsumoto, Shunichiro [1 ]
Kawaguchi, Kenichi [1 ]
Kazami, Junichi [1 ]
Toyoshima, Akira [1 ]
Kita, Aya [1 ]
Tominaga, Fumiko [1 ]
Okada, Minoru [1 ]
Ohta, Mitsuaki [1 ]
机构：
[1] Astellas Pharma Inc, Drug Discovery Res, Tsukuba, Ibaraki 3058585, Japan
来源：
ABSTRACTS OF PAPERS OF THE AMERICAN CHEMICAL SOCIETY | 2007年 / 234卷
关键词：
D O I：
暂无
中图分类号：
O6 [化学];
学科分类号：
0703 ;
摘要：
312-MEDI
引用
收藏
页数：1
相关论文
共 50 条
  • [1] The survivin suppressant YM155 reverses doxorubicin resistance in osteosarcoma
    Zhang, Zhuo
    Zhang, Yunfeng
    Lv, Jiayin
    Wang, Jincheng
    INTERNATIONAL JOURNAL OF CLINICAL AND EXPERIMENTAL MEDICINE, 2015, 8 (10): : 18032 - 18040
  • [2] Carrier-mediated uptake of YM155, a novel survivin suppressant, into human cancer cells in vitro
    Minematsu, Tsuyoshi
    Iwai, Megumi
    Nakahara, Takahito
    Usui, Takashi
    Kamimura, Hidetaka
    DRUG METABOLISM REVIEWS, 2006, 38 : 112 - 112
  • [3] Predicting response to sepantronium bromide (YM155), a survivin suppressant, by PET imaging with [11C]YM155
    Mitsuoka, Keisuke
    Kita, Aya
    Murakami, Yoshihiro
    Shirasuna, Kenna
    Noda, Akihiro
    Yamanaka, Kentaro
    Kaneko, Naoki
    Miyoshi, Sosuke
    NUCLEAR MEDICINE AND BIOLOGY, 2018, 64-65 : 41 - 46
  • [4] Phase I Study of YM155, a Novel Survivin Suppressant, in Patients with Advanced Solid Tumors
    Satoh, Taroh
    Okamoto, Isamu
    Miyazaki, Masaki
    Morinaga, Ryotaroh
    Tsuya, Asuka
    Hasegawa, Yoshikazu
    Terashima, Masaaki
    Ueda, Shinya
    Fukuoka, Masahiro
    Ariyoshi, Yutaka
    Saito, Toshikazu
    Masuda, Noriyuki
    Watanabe, Hirokazu
    Taguchi, Tetsuo
    Kakihara, Toru
    Aoyama, Yumiko
    Hashimoto, Yohko
    Nakagawa, Kazuhiko
    CLINICAL CANCER RESEARCH, 2009, 15 (11) : 3872 - 3880
  • [5] YM155, a novel survivin suppressant, demonstrates activity in subjects with stage III or IV melanoma
    Gonzalez, R.
    Samlowski, W.
    Cranmer, L.
    Catlett, J.
    Whitman, E.
    Lawson, D.
    Lewis, K.
    Drake, T.
    Bartels, P.
    Buell, D.
    Keating, A.
    Kirkwood, J.
    ANNALS OF ONCOLOGY, 2007, 18 : 40 - 40
  • [6] Induction of autophagy-dependent apoptosis by the survivin suppressant YM155 in prostate cancer cells
    Wang, Qinwen
    Chen, Zhengtang
    Diao, Xinwei
    Huang, Shengbing
    CANCER LETTERS, 2011, 302 (01) : 29 - 36
  • [7] Survivin suppressant YM155: A pharmacokinetic comparison between US and Japanese populations
    Cao, Ying J.
    Aoyama, Yumiko
    Kakihara, Toru
    Katashima, Masataka
    Sawamoto, Taiji
    Roy, Michael
    Wang, Jimmy
    Abeyratne, Anura
    Nakahara, Takahito
    Steinberg, Joyce
    Keating, Anne
    MOLECULAR CANCER THERAPEUTICS, 2009, 8 (12)
  • [8] Antitumor activity of YM155, a selective survivin suppressant, in combination with cisplatin in hepatoblastoma
    Yu, Ying
    Zhao, Xiaosu
    Zhang, Yu
    Kang, Yanling
    Wang, Jiaqi
    Liu, Yingchun
    ONCOLOGY REPORTS, 2015, 34 (01) : 407 - 414
  • [9] YM155, a Novel Small-Molecule Survivin Suppressant, Combined With Radiation Therapy in Prostate Cancer Cell Lines
    Thoms, J.
    Aoki, S.
    INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS, 2013, 87 (02): : S648 - S648
  • [10] Involvement of Multidrug Resistance 1 (MDR1) for the Pharmacokinetics of YM155, a Novel Survivin Suppressant
    Iwai, Megumi
    Minematsu, Tsuyoshi
    Li, Qun
    Iwatsubo, Takafumi
    Usui, Takashi
    DRUG METABOLISM REVIEWS, 2010, 42 : 288 - 289
12345